RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Sponsor: Eli Lilly and Company
Nashville, TN · +21 more sites
Breast Cancer clinical trials in Nashville, TN
46 recruiting breast cancer studies with a site in Nashville, TN.
RecruitingPhase 1NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Sponsor: BeOne Medicines
Nashville, TN · +8 more sites
RecruitingPhase 1NCT06545331
Study of XB010 in Subjects With Solid Tumors
Sponsor: Exelixis
Nashville, TN · +15 more sites
RecruitingPhase 3NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Sponsor: Merck Sharp & Dohme LLC
Nashville, TN · +37 more sites
RecruitingPhase 3NCT07174336
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Sponsor: Eli Lilly and Company
Nashville, TN · +127 more sites
RecruitingPhase 1 / Phase 2NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor: Genmab
Nashville, TN · +35 more sites
RecruitingPhase 3NCT06790693
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Sponsor: Hoffmann-La Roche
Germantown, TN · Nashville, TN · +60 more sites
RecruitingPhase 1NCT06840886
A Study of PHST001 in Advanced Solid Tumors
Sponsor: Pheast Therapeutics
Nashville, TN · +18 more sites
RecruitingPhase 3NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Knoxville, TN · Nashville, TN · +50 more sites
RecruitingPhase 1NCT06270706
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Sponsor: Pliant Therapeutics, Inc.
Nashville, TN · +15 more sites
RecruitingPhase 2NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Sponsor: Bayer
Nashville, TN · +10 more sites
RecruitingPhase 2NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Sponsor: Daiichi Sankyo
Nashville, TN · +12 more sites
RecruitingPhase 1NCT05877599
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Sponsor: AstraZeneca
Nashville, TN · +19 more sites
RecruitingPhase 2NCT07427394
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Sponsor: AstraZeneca
Nashville, TN · +2 more sites
RecruitingNot applicableNCT07214532
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
Germantown, TN · Nashville, TN · +47 more sites
RecruitingPhase 1NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Sponsor: SystImmune Inc.
Nashville, TN · +21 more sites
RecruitingPhase 1 / Phase 2NCT05898399
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Sponsor: Artios Pharma Ltd
Nashville, TN · +6 more sites
RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Memphis, TN · Nashville, TN · +173 more sites
RecruitingPhase 2NCT06797635
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Sponsor: Merck Sharp & Dohme LLC
Nashville, TN · +7 more sites
RecruitingPhase 1NCT06440005
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Sponsor: Angiex, Inc.
Nashville, TN · +6 more sites
RecruitingPhase not listedNCT07211178
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Sponsor: Tempus AI
Nashville, TN · +15 more sites
RecruitingPhase 2NCT05919108
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Sponsor: Vanderbilt-Ingram Cancer Center
Nashville, TN · +4 more sites
RecruitingPhase 1NCT07182149
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Sponsor: Normunity AccelCo, Inc.
Nashville, TN · +17 more sites
RecruitingPhase 1 / Phase 2NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Nashville, TN · +9 more sites
RecruitingPhase 3NCT05232916
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Sponsor: Greenwich LifeSciences, Inc.
Knoxville, TN · Nashville, TN · +49 more sites
RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Collierville, TN · Knoxville, TN · Memphis, TN · +825 more sites
RecruitingPhase 1 / Phase 2NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Sponsor: Daiichi Sankyo
Chattanooga, TN · Germantown, TN · Nashville, TN · +15 more sites
RecruitingPhase 3NCT06748222
E-Mindfulness Approaches for Living After Breast Cancer
Sponsor: NRG Oncology
Knoxville, TN · Memphis, TN · Nashville, TN · +378 more sites
RecruitingPhase 1NCT06545942
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Sponsor: MOMA Therapeutics
Nashville, TN · +11 more sites
RecruitingPhase 2NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Sponsor: Jazz Pharmaceuticals
Knoxville, TN · Nashville, TN · +15 more sites
RecruitingPhase 1 / Phase 2NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Sponsor: Eli Lilly and Company
Germantown, TN · Nashville, TN · +26 more sites
RecruitingPhase 1NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Nashville, TN · +105 more sites
RecruitingPhase 1NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
Sponsor: Eli Lilly and Company
Nashville, TN · +14 more sites
RecruitingEarly Phase 1NCT06828588
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Sponsor: Vanderbilt-Ingram Cancer Center
Nashville, TN
RecruitingPhase 2NCT04434040
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Sponsor: Dana-Farber Cancer Institute
Nashville, TN · +6 more sites
RecruitingPhase 3NCT04852887
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Sponsor: NRG Oncology
Knoxville, TN · Nashville, TN · +809 more sites
RecruitingPhase not listedNCT03448926
The PREDICT Registry:
Sponsor: PreludeDx
Nashville, TN · +29 more sites
RecruitingPhase 1 / Phase 2NCT05785741
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
Nashville, TN · +14 more sites
RecruitingPhase 2NCT05748834
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Sponsor: SCRI Development Innovations, LLC
Nashville, TN · +6 more sites
RecruitingPhase 3NCT06435429
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Sponsor: Jazz Pharmaceuticals
Nashville, TN · +47 more sites
RecruitingPhase 1 / Phase 2NCT06926920
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Sponsor: Gilead Sciences
Germantown, TN · Nashville, TN · +6 more sites
RecruitingPhase 2NCT05693766
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Sponsor: Sonya Reid
Nashville, TN · +2 more sites
RecruitingPhase 1 / Phase 2NCT06827613
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Sponsor: Marengo Therapeutics, Inc.
Nashville, TN · +5 more sites
RecruitingPhase 1NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Nashville, TN · +23 more sites
RecruitingPhase 1 / Phase 2NCT04503265
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Sponsor: AtlasMedx, Incorporated
Nashville, TN · +3 more sites
RecruitingPhase 1NCT04872166
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Sponsor: Edgewood Oncology Inc.
Nashville, TN · +4 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.